ArticleCVIR endovascular2025
Endovascular management of acquired uterine vascular anomalies.
Article in CVIR endovascular, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CIRSE Standards of Practice for the Use of Non-sclerosant Liquid Embolic Agents in IR Practice.Cardiovascular and interventional radiology · 2026Article
- Embolization therapy for pelvic arteriovenous malformations: a systematic review.CVIR endovascular · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate clinical presentation, imaging features, embolization techniques and their outcome for acquired uterine vascular anomalies (UVA) related to obstetric events. MATERIALS AND
methodsThirteen women (mean age = 34; range = 20-40 years) who had undergone interventional radiological treatment of UVAs between 2013 and 2024 were retrospectively analyzed. All patients had a history of an obstetric event. They presented with ongoing postpartal vaginal blood losses (n = 11) or were asymptomatic (n = 2). Fertilization had been performed by intracytoplasmic sperm injection (ICSI) in 3/13 women. 7/13 women had delivered healthy babies. 6 women had surgical, drug-induced or missed abortions. Postpartum dilatation and curettage had been performed in 4 women. The delay between the obstetric/gynecological event and the radiological intervention ranged from 19 to 193 days (median = 49 days). Long-term follow-up was available in 12/13 patients (median FU = 2.4 years). Unilateral selective transcatheter embolization was performed in 7/12 patients (n-Butyl-Cyanoacrylate-Lipiodol mixture [BCAL], n = 5; trisacryl gelatine particles, n = 2); Bilateral uterine artery embolization was performed in 5/12 women (unilateral BCAL combined with contralateral particles in 3/12, or bilateral gelatine sponge slurry in 2/12). In one patient percutaneous direct injection of BCAL into a uterine artery branch pseudoaneurysm was performed.
resultsPrimary clinical success without complications was achieved in 10/13 interventions. Re-embolization was successful in the 3 patients with ongoing bleeding despite uterine artery embolization. Follow-up information was available in 12/13 patients (median FU = 2.4 yrs). The pregnancy rate after embolization was 8/12women with a birth rate of 6/8 pregnancies.
conclusionEmbolization of acquired UVAs is an effective and safe treatment. Preservation of uterine function for future pregnancy after uterine transarterial embolization seems warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.